Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
Background: Treatment of multidrug-resistant tuberculosis (MDR-TB) in the Programmatic Management of Drug-resistant TB program involves a standard regimen with a 6-month intensive phase and an 18-month continuation phase. However, the local drug resistance patterns in high MDR regions such as Mumbai...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Lung India |
| Subjects: | |
| Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2016;volume=33;issue=3;spage=253;epage=256;aulast=Udwadia |
| _version_ | 1819267550477811712 |
|---|---|
| author | Zarir F Udwadia Jai Bharat Mullerpattan Kushal D Shah Camilla S Rodrigues |
| author_facet | Zarir F Udwadia Jai Bharat Mullerpattan Kushal D Shah Camilla S Rodrigues |
| author_sort | Zarir F Udwadia |
| collection | DOAJ |
| description | Background: Treatment of multidrug-resistant tuberculosis (MDR-TB) in the Programmatic Management of Drug-resistant TB program involves a standard regimen with a 6-month intensive phase and an 18-month continuation phase. However, the local drug resistance patterns in high MDR regions such as Mumbai may not be adequately reflected in the design of the regimen for that particular area. Setting: The study was carried out at a private Tertiary Level Hospital in Mumbai in a mycobacteriology laboratory equipped to perform the second-line drug susceptibility testing (DST). Objective: We attempted to analyze the impact of prescribing the standardized Category IV regimen to all patients receiving a DST at our mycobacteriology laboratory. Materials and Methods: All samples confirmed to be MDR-TB and tested for the second-line drugs at Hinduja Hospital′s Mycobacteriology Laboratory in the year 2012 were analyzed. Results: A total of 1539 samples were analyzed. Of these, 464 (30.14%) were MDR-TB, 867 (56.33%) were MDR with fluoroquinolone resistance, and 198 (12.8%) were extensively drug-resistant TB. The average number of susceptible drugs per sample was 3.07 ± 1.29 (assuming 100% cycloserine susceptibility). Taking 4 effective drugs to be the cut or an effective regimen, the number of patients receiving 4 or more effective drugs from the standardized directly observed treatment, short-course plus regimen would be 516 (33.5%) while 66.5% of cases would receive 3 or less effective drugs. Conclusion: Our study shows that a high proportion of patients will have resistance to a number of the first- and second-line drugs. Local epidemiology must be factored in to avoid amplification of resistance. |
| first_indexed | 2024-12-23T21:18:57Z |
| format | Article |
| id | doaj.art-88f58ee263b74039809559a62f7064e5 |
| institution | Directory Open Access Journal |
| issn | 0970-2113 0974-598X |
| language | English |
| last_indexed | 2024-12-23T21:18:57Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Lung India |
| spelling | doaj.art-88f58ee263b74039809559a62f7064e52022-12-21T17:30:49ZengWolters Kluwer Medknow PublicationsLung India0970-21130974-598X2016-01-0133325325610.4103/0970-2113.180800Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in MumbaiZarir F UdwadiaJai Bharat MullerpattanKushal D ShahCamilla S RodriguesBackground: Treatment of multidrug-resistant tuberculosis (MDR-TB) in the Programmatic Management of Drug-resistant TB program involves a standard regimen with a 6-month intensive phase and an 18-month continuation phase. However, the local drug resistance patterns in high MDR regions such as Mumbai may not be adequately reflected in the design of the regimen for that particular area. Setting: The study was carried out at a private Tertiary Level Hospital in Mumbai in a mycobacteriology laboratory equipped to perform the second-line drug susceptibility testing (DST). Objective: We attempted to analyze the impact of prescribing the standardized Category IV regimen to all patients receiving a DST at our mycobacteriology laboratory. Materials and Methods: All samples confirmed to be MDR-TB and tested for the second-line drugs at Hinduja Hospital′s Mycobacteriology Laboratory in the year 2012 were analyzed. Results: A total of 1539 samples were analyzed. Of these, 464 (30.14%) were MDR-TB, 867 (56.33%) were MDR with fluoroquinolone resistance, and 198 (12.8%) were extensively drug-resistant TB. The average number of susceptible drugs per sample was 3.07 ± 1.29 (assuming 100% cycloserine susceptibility). Taking 4 effective drugs to be the cut or an effective regimen, the number of patients receiving 4 or more effective drugs from the standardized directly observed treatment, short-course plus regimen would be 516 (33.5%) while 66.5% of cases would receive 3 or less effective drugs. Conclusion: Our study shows that a high proportion of patients will have resistance to a number of the first- and second-line drugs. Local epidemiology must be factored in to avoid amplification of resistance.http://www.lungindia.com/article.asp?issn=0970-2113;year=2016;volume=33;issue=3;spage=253;epage=256;aulast=UdwadiaCategory IV treatmentdirectly observed treatment short-course plusdrug-resistant tuberculosis |
| spellingShingle | Zarir F Udwadia Jai Bharat Mullerpattan Kushal D Shah Camilla S Rodrigues Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai Lung India Category IV treatment directly observed treatment short-course plus drug-resistant tuberculosis |
| title | Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai |
| title_full | Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai |
| title_fullStr | Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai |
| title_full_unstemmed | Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai |
| title_short | Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai |
| title_sort | possible impact of the standardized category iv regimen on multidrug resistant tuberculosis patients in mumbai |
| topic | Category IV treatment directly observed treatment short-course plus drug-resistant tuberculosis |
| url | http://www.lungindia.com/article.asp?issn=0970-2113;year=2016;volume=33;issue=3;spage=253;epage=256;aulast=Udwadia |
| work_keys_str_mv | AT zarirfudwadia possibleimpactofthestandardizedcategoryivregimenonmultidrugresistanttuberculosispatientsinmumbai AT jaibharatmullerpattan possibleimpactofthestandardizedcategoryivregimenonmultidrugresistanttuberculosispatientsinmumbai AT kushaldshah possibleimpactofthestandardizedcategoryivregimenonmultidrugresistanttuberculosispatientsinmumbai AT camillasrodrigues possibleimpactofthestandardizedcategoryivregimenonmultidrugresistanttuberculosispatientsinmumbai |